Vnitr Lek 2025, 71(4):207-212
Hlavní téma: Pneumologie up-to-date
- Plicní klinika FN HK a LF HK UK
Published: June 19, 2025 Show citation
References
- Chronic respiratory diseases. Data from 2025. WHO. Anotace. [cit. 2025-05-18]. Available from: .
- Májek, O., Koziar Vašáková, M., Čierna Peterová, I., et al. PrevenceProPlice.cz - Program časného záchytu karcinomu plic. Praha: Ústav zdravotnických informací a statistiky ČR, 2022. [cit. 2025-05-18]. Available from:
- Ward B, Koziar Vašáková M, Robalo Cordeiro C, et al. Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer screening. ERJ Open Res. 2023;9(3):00026-2023. doi: 10.1183/23120541.00026-2023.
Go to original source...
Go to PubMed...
- Althobiani MA, Russell AM, Jacob J, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med. 2024;11:1296890. doi: 10.3389/fmed.2024.1296890.
Go to original source...
Go to PubMed...
- Venkatesan P. GOLD COPD report: 2025 update. Lancet Respir Med. 2025;13(1):e7-e8. doi: 10.1016/S2213-2600(24)00413-2.
Go to original source...
Go to PubMed...
- Matera MG, Rinaldi B, Annibale R, et al. The pharmacological management of asthma in adults: 2023 update. Expert Opin Pharmacother. 2024;25(4):383-393. doi: 10.1080/14656566.2024.2332627.
Go to original source...
Go to PubMed...
- Horváth I, Canotilho M, Chlumský J, et al. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1):00171-2018. doi: 10.1183/23120541.00171-2018.
Go to original source...
Go to PubMed...
- Fila L. Cystická fibróza dospělých. Vnitř Lék. 2017; 63(11):834-842.
Go to original source...
- Keating C, Yonker LM, Vermeulen F et al; VX20-121-102 Study Group; VX20-121-103 Study Group. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025; 13(3):256-271.
Go to original source...
Go to PubMed...